1. Anti-infection
    Metabolic Enzyme/Protease
  2. HCV
    HCV Protease

Daclatasvir dihydrochloride (Synonyms: BMS-790052 dihydrochloride)

Cat. No.: HY-10465 Purity: 99.70%
Data Sheet SDS Handling Instructions

BMS-790052 is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture.

For research use only. We do not sell to patients.
Daclatasvir dihydrochloride Chemical Structure

Daclatasvir dihydrochloride Chemical Structure

CAS No. : 1009119-65-6

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $67 In-stock
5 mg $50 In-stock
10 mg $75 In-stock
50 mg $150 In-stock
100 mg $190 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Other Forms of Daclatasvir dihydrochloride:

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

BMS-790052 is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. IC50 Value: 9-50 pM Target: HCV NS5A BMS-790052 has broad genotype coverage and exhibits picomolar in vitro potency against genotypes 1a (EC50 50pm) and 1b (EC50 9pm). BMS-790052 produces a robust decline in HCV RNA (-3.6 logs after 48 hours from a single 100 mg) dosefollowing a single dose in patients chronically infected with HCV genotype 1.

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01492504 Bristol-Myers Squibb Hepatitis C February 7, 2012
NCT00859053 Bristol-Myers Squibb Hepatic Insufficiency March 2009 Phase 1
NCT00983957 Bristol-Myers Squibb Chronic Hepatitis C October 2009 Phase 1
NCT01448044 Bristol-Myers Squibb Hepatitis C December 2011 Phase 3
NCT01497834 Bristol-Myers Squibb Hepatitis C January 2012 Phase 3
NCT01170962 Bristol-Myers Squibb Hepatitis C Virus August 2010 Phase 2
NCT01051414 Bristol-Myers Squibb Hepatitis C Infection April 2010 Phase 2
NCT01016912 Bristol-Myers Squibb Hepatitis C Infection December 2009 Phase 2
NCT02161939 Bristol-Myers Squibb Chronic Hepatitis C
NCT00904059 Bristol-Myers Squibb Hepatitis C May 2009 Phase 1
NCT01309932 Bristol-Myers Squibb Hepatitis C March 2011 Phase 2
NCT01455090 Bristol-Myers Squibb Chronic Hepatitis C November 30, 2011 Phase 2
NCT01012895 Bristol-Myers Squibb Chronic Hepatitis C December 2009 Phase 2
NCT01492504 Bristol-Myers Squibb Hepatitis C February 7, 2012
NCT00859053 Bristol-Myers Squibb Hepatic Insufficiency March 2009 Phase 1
NCT00983957 Bristol-Myers Squibb Chronic Hepatitis C October 2009 Phase 1
NCT01448044 Bristol-Myers Squibb Hepatitis C December 2011 Phase 3
NCT01497834 Bristol-Myers Squibb Hepatitis C January 2012 Phase 3
NCT01170962 Bristol-Myers Squibb Hepatitis C Virus August 2010 Phase 2
NCT01051414 Bristol-Myers Squibb Hepatitis C Infection April 2010 Phase 2
NCT01016912 Bristol-Myers Squibb Hepatitis C Infection December 2009 Phase 2
NCT02161939 Bristol-Myers Squibb Chronic Hepatitis C
NCT00904059 Bristol-Myers Squibb Hepatitis C May 2009 Phase 1
NCT01309932 Bristol-Myers Squibb Hepatitis C March 2011 Phase 2
NCT01455090 Bristol-Myers Squibb Chronic Hepatitis C November 30, 2011 Phase 2
NCT01012895 Bristol-Myers Squibb Chronic Hepatitis C December 2009 Phase 2
NCT02865369 Sang Gyune Kim|Seoul National University Boramae Hospital|Severance Hospital|Inha University Hospital|Korea University|Gachon University Gil Medical Center|Hanyang University Seoul Hospital|Ewha Womans University Mokdong Hospital|Bristol-Myers Squibb|Soonchunhyang University Hospital Chronic Hepatitis C September 2016
NCT01830205 Bristol-Myers Squibb Hepatitis C September 2012 Phase 1
NCT02032901 Bristol-Myers Squibb Hepatitis C January 2014 Phase 3
NCT03004625 Kaohsiung Medical University Chung-Ho Memorial Hospital|Chang Gung Memorial Hospital|National Taiwan University Hospital|Taipei Veterans General Hospital, Taiwan|China Medical University Hospital|National Cheng-Kung University Hospital Hepatitis C November 2016 Phase 3
NCT02159352 Bristol-Myers Squibb Hepatitis C June 2014 Phase 1
NCT02268864 Janssen-Cilag International NV Hepatitis C, Chronic January 2015 Phase 2
NCT02624063 Federal University of São Paulo Hepatitis C, Chronic December 2015 Phase 4
NCT02756936 Genuine Research Center, Egypt|Zeta Pharma Pharmaceutical Industries Healthy February 2016 Phase 1
NCT02032888 Bristol-Myers Squibb Hepatitis C February 2014 Phase 3
NCT02551861 Bristol-Myers Squibb Hepatitis C December 2015 Phase 2
NCT02565862 Radboud University Hepatitis C|Diabetes Mellitus|Insulin Resistance January 2016 Phase 1
NCT02124044 National Institutes of Health Clinical Center (CC)|National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb HIV-HCV February 2014 Phase 2
NCT03063879 Tehran University of Medical Sciences|Ahvaz Jundishapur University of Medical Sciences|Shiraz University of Medical Sciences|Hamadan University of Medical Science Hepatitis C, Chronic|Chronic Renal Failure April 1, 2017 Phase 4
NCT02262728 Janssen Research & Development, LLC Hepatitis C, Chronic September 2014 Phase 2
NCT02309450 French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb Hepatitis C Virus Genotype 4 Infection December 2014 Phase 2
NCT02640157 AbbVie Chronic Hepatitis C|Hepatitis C Virus|Genotype 3 Hepatitis C Virus December 2015 Phase 3
NCT02556086 Bristol-Myers Squibb Hepatitis C December 2015 Phase 2
NCT02580474 Myeong Jun Song|Bristol-Myers Squibb|Soonchunhyang University Hospital|Dankook University|Chungnam National University Hospital|Konyang University Hospital|Eulji University Hospital|Saint Vincent's Hospital, Korea|Konkuk University Hospital|Cheongju St. Mary's Hospital, Cheongju, Korea|Severance Hospital|Korea University Guro Hospital|Eulji General Hospital|The Catholic University of Korea Hepatitis C February 2016 Phase 4
NCT01842451 Vertex Pharmaceuticals Incorporated Chronic Hepatitis C|CHC|HCV|Hepatitis C June 2013 Phase 2
NCT02496078 Bristol-Myers Squibb Hepatitis C August 2015 Phase 3
NCT01628692 Bristol-Myers Squibb|Janssen Research & Development, LLC Hepatitis C Virus July 2012 Phase 2
NCT02032875 Bristol-Myers Squibb Hepatitis C March 2014 Phase 3
NCT02397395 Janssen R&D Ireland Renal Impairment|End-stage Renal Disease May 2015 Phase 2
NCT02596880 Tehran University of Medical Sciences Hepatitis C|Cirrhosis September 2015 Phase 3
NCT01797848 Bristol-Myers Squibb Hepatitis C June 2014 Phase 3
NCT03200184 Tehran University of Medical Sciences Hepatitis C September 1, 2016 Phase 4
NCT02319031 Bristol-Myers Squibb Hepatitis C February 2015 Phase 3
NCT01995266 Bristol-Myers Squibb Hepatitis C February 2014 Phase 3
NCT02565888 Radboud University Hepatitis C|HIV November 2015 Phase 1
NCT02123654 Bristol-Myers Squibb Hepatitis C Virus Infection April 2014 Phase 3
NCT02107365 French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb Hepatitis C Virus Genotype 4 Infection November 2013 Phase 2
NCT02304159 Tarek I. Hassanein, M.D., FACP, FAG, AGAF|Southern California Research Center Hepatitis C|Cirrhosis January 2015 Phase 4
NCT02097966 Bristol-Myers Squibb Chronic Hepatitis C
NCT02349048 Janssen Research & Development, LLC Hepatitis C Virus January 2015 Phase 2
NCT02104843 Bristol-Myers Squibb Hepatitis C April 2014 Phase 1
NCT00663208 Bristol-Myers Squibb Chronic Hepatitis C May 2008 Phase 2
NCT02473211 Humanity & Healthy GI and Liver Centre|Beijing 302 Hospital Chronic Hepatitis C Infection January 2015 Phase 2|Phase 3
NCT01492426 Bristol-Myers Squibb Hepatitis C January 2012 Phase 3
NCT01718158 Bristol-Myers Squibb Hepatitis C January 2013 Phase 3
NCT01938625 Janssen R&D Ireland Hepatitis C, Chronic December 2013 Phase 2
NCT01718145 Bristol-Myers Squibb Hepatitis C Virus Infection November 2012 Phase 3
NCT01389323 Bristol-Myers Squibb Hepatitis C September 2011 Phase 3
NCT00546715 Bristol-Myers Squibb Chronic Hepatitis C November 2007 Phase 1|Phase 2
NCT02323594 Bristol-Myers Squibb Hepatitis C Infection December 2014 Phase 1
NCT01725542 French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb HCV-HIV Co-Infection December 2012 Phase 2
NCT01125189 Bristol-Myers Squibb Hepatitis C Virus July 2010 Phase 2
NCT01425970 Bristol-Myers Squibb Hepatitis C May 2012 Phase 2
NCT01866930 Bristol-Myers Squibb Chronic Hepatitis C Infection July 11, 2013 Phase 3
NCT01629732 Bristol-Myers Squibb Hepatitis C Virus March 2013 Phase 2
NCT01616524 Bristol-Myers Squibb Hepatitis C Virus (HCV) July 2012 Phase 3
NCT01471574 Bristol-Myers Squibb Hepatitis C, Genotype 1 December 2011 Phase 3
NCT02762448 Tainan Municipal Hospital Hepatitis c July 2017
NCT01017575 Bristol-Myers Squibb Hepatitis C Infection December 2009 Phase 2
NCT01428063 Bristol-Myers Squibb Hepatitis C Virus Infection September 2011 Phase 2
NCT01795911 Bristol-Myers Squibb Hepatitis C March 2013 Phase 2
NCT00874770 Bristol-Myers Squibb Hepatitis C Infection June 2009 Phase 2
NCT02103569 Bristol-Myers Squibb Hepatitis C April 2014 Phase 1
NCT01359644 Bristol-Myers Squibb|Pharmasset Chronic Hepatitis C June 2011 Phase 2
NCT03186313 Egyptian Liver Hospital|Wadi El Nil Hospital Hepatitis C September 2016 Phase 3
NCT01573351 Bristol-Myers Squibb Hepatitis C Virus May 2012 Phase 3
NCT01741545 Bristol-Myers Squibb Hepatitis C Virus March 2013 Phase 3
NCT01257204 Bristol-Myers Squibb Hepatitis C Virus December 2010 Phase 2
NCT02576314 Humanity & Healthy GI and Liver Centre|Beijing 302 Hospital Chronic Hepatitis C Infection May 2015 Phase 3
NCT03188276 Third Affiliated Hospital, Sun Yat-Sen University Chronic Hepatitis C February 1, 2016 Early Phase 1
NCT03166280 Eman Sayed Hassan Abd Allah|Assiut University Hepatitis C June 2017
NCT02657694 FixHepC Hepatitis C July 1, 2015
NCT02282709 Foundation for Liver Research Chronic Hepatitis C February 2014 Phase 3
NCT01973049 Bristol-Myers Squibb Hepatitis C December 2013 Phase 3
NCT01581203 Bristol-Myers Squibb Hepatitis C Virus May 2012 Phase 3
NCT03063723 Third Affiliated Hospital, Sun Yat-Sen University Chronic Hepatitis C (Disorder) January 1, 2016
NCT02772744 Zagazig University|Cairo University Hepatitis C June 2016
NCT03163849 Assiut University Chronic Hepatitis c December 1, 2017 Phase 3
NCT02771405 National Hepatology & Tropical Medicine Research Institute|Cairo University Hepatitis C, Chronic|Hepatocellular Carcinoma March 2016 Phase 3
NCT03169348 Assiut University Hepatitis C November 1, 2017
NCT02555943 Humanity & Healthy GI and Liver Centre|Beijing 302 Hospital|Nanfang Hospital of Southern Medical University Chronic Hepatitis C Infection|HBV Coinfection|Hepatitis B Reactivation February 2015 Phase 2|Phase 3
NCT02992457 Tanta University Hepatitis C December 2016 Phase 4
NCT02758509 Parc de Salut Mar Chronic Hepatitis C|Cirrhosis January 1, 2010
NCT02333292 Valme University Hospital|Hospital del SAS de Jerez|Hospital General Universitario Elche|Hospital La Línea de la Concepción|Complexo Hospitalario Universitario de A Coruña|Hospital de Figueres|Hospital Universitario Puerto Real|Hospital Universitario Virgen de la Victoria|Hospital Universitario de Canarias|Hospital General Universitario de Alicante|Hospital Universitario Araba|Hospital Royo Vilanova|Hospital Universitario de Burgos|Complejo Hospitalario Universitario de Huelva|Hospital Universitario Reina Sofia|Hospital Universitario Virgen Macarena|Complexo Hospitalario Universitario de Vigo|Clinica Universidad de Navarra, Universidad de Navarra|Hospital Clinico Universitario San Cecilio|Hospital Universitario La Fe|Hospital General Universitario de Valencia|Hospital Universitario Infanta Leonor|Hospital Universitario de Gran Canaria|Hospital General Universitario Santa Lucía|Centro Penitenciario Alicante 1|Hospital Regional Universitario Carlos Haya|Hospital Virgen de la Luz|Hospital General Universitario de Castellón|Hospital Parc Taulí, Sabadell Chronic Hepatitis C Infection December 2014
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 1.2318 mL 6.1592 mL 12.3183 mL
5 mM 0.2464 mL 1.2318 mL 2.4637 mL
10 mM 0.1232 mL 0.6159 mL 1.2318 mL
References
Molecular Weight

811.8

Formula

C₄₀H₅₂Cl₂N₈O₆

CAS No.

1009119-65-6

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 56 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Daclatasvir dihydrochloride
Cat. No.:
HY-10465
Quantity: